File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Anxiolytic Effects of Chronic Intranasal Oxytocin on Neural Responses to Threat Are Dose-Frequency Dependent

TitleAnxiolytic Effects of Chronic Intranasal Oxytocin on Neural Responses to Threat Are Dose-Frequency Dependent
Authors
KeywordsAmygdala
Anxiety
Chronic oxytocin
fMRI
Issue Date2022
Citation
Psychotherapy and Psychosomatics, 2022, v. 91, n. 4, p. 253-264 How to Cite?
AbstractIntroduction: Anxiety disorders are prevalent mental conditions characterized by exaggerated anxious arousal and threat reactivity. Animal and human studies suggest an anxiolytic potential of the neuropeptide oxytocin (OT), yet, while a clinical application will require chronic administration protocols, previous human studies have exclusively focused on single-dose (acute) intranasal OT effects. Objective: To facilitate the translation of the potential anxiolytic mechanism of OT into clinical application, we determined whether the anxiolytic effects of OT are maintained with repeated (chronic) administration or are influenced by dose frequency and trait anxiety. Methods: In a pre-registered double-blind randomized placebo-controlled pharmaco-fMRI trial the acute (single dose) as well as chronic effects of two different dose frequencies of OT (OT administered daily for 5 days or every other day) on emotional reactivity were assessed in n = 147 individuals with high versus low trait anxiety (ClinicalTrials.gov ID: NCT03085654). Results: OT produced valence, dose frequency, and trait anxiety-specific effects, such that the low-frequency (intermittent) chronic dosage specifically attenuated a neural reactivity increase in amygdala-insula-prefrontal circuits observed in the high anxious placebo-treated subjects in response to threatening but not positive stimuli. Conclusions: The present trial provides the first evidence that low-dose frequency chronic intranasal OT has the potential to alleviate exaggerated neural threat reactivity in subjects with elevated anxiety levels, suggesting a treatment potential for anxiety disorders.
Persistent Identifierhttp://hdl.handle.net/10722/330764
ISSN
2023 Impact Factor: 16.3
2023 SCImago Journal Rankings: 5.104
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorKou, Juan-
dc.contributor.authorZhang, Yingying-
dc.contributor.authorZhou, Feng-
dc.contributor.authorGao, Zhao-
dc.contributor.authorYao, Shuxia-
dc.contributor.authorZhao, Weihua-
dc.contributor.authorLi, Hong-
dc.contributor.authorLei, Yi-
dc.contributor.authorGao, Shan-
dc.contributor.authorKendrick, Keith M.-
dc.contributor.authorBecker, Benjamin-
dc.date.accessioned2023-09-05T12:14:01Z-
dc.date.available2023-09-05T12:14:01Z-
dc.date.issued2022-
dc.identifier.citationPsychotherapy and Psychosomatics, 2022, v. 91, n. 4, p. 253-264-
dc.identifier.issn0033-3190-
dc.identifier.urihttp://hdl.handle.net/10722/330764-
dc.description.abstractIntroduction: Anxiety disorders are prevalent mental conditions characterized by exaggerated anxious arousal and threat reactivity. Animal and human studies suggest an anxiolytic potential of the neuropeptide oxytocin (OT), yet, while a clinical application will require chronic administration protocols, previous human studies have exclusively focused on single-dose (acute) intranasal OT effects. Objective: To facilitate the translation of the potential anxiolytic mechanism of OT into clinical application, we determined whether the anxiolytic effects of OT are maintained with repeated (chronic) administration or are influenced by dose frequency and trait anxiety. Methods: In a pre-registered double-blind randomized placebo-controlled pharmaco-fMRI trial the acute (single dose) as well as chronic effects of two different dose frequencies of OT (OT administered daily for 5 days or every other day) on emotional reactivity were assessed in n = 147 individuals with high versus low trait anxiety (ClinicalTrials.gov ID: NCT03085654). Results: OT produced valence, dose frequency, and trait anxiety-specific effects, such that the low-frequency (intermittent) chronic dosage specifically attenuated a neural reactivity increase in amygdala-insula-prefrontal circuits observed in the high anxious placebo-treated subjects in response to threatening but not positive stimuli. Conclusions: The present trial provides the first evidence that low-dose frequency chronic intranasal OT has the potential to alleviate exaggerated neural threat reactivity in subjects with elevated anxiety levels, suggesting a treatment potential for anxiety disorders.-
dc.languageeng-
dc.relation.ispartofPsychotherapy and Psychosomatics-
dc.subjectAmygdala-
dc.subjectAnxiety-
dc.subjectChronic oxytocin-
dc.subjectfMRI-
dc.titleAnxiolytic Effects of Chronic Intranasal Oxytocin on Neural Responses to Threat Are Dose-Frequency Dependent-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1159/000521348-
dc.identifier.pmid35086102-
dc.identifier.scopuseid_2-s2.0-85124618416-
dc.identifier.volume91-
dc.identifier.issue4-
dc.identifier.spage253-
dc.identifier.epage264-
dc.identifier.eissn1423-0348-
dc.identifier.isiWOS:000750619900001-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats